DSIP dosage

DSIP injectable dosage

Reported-use amounts for DSIP are 100–300 mcg per administration, nightly, for 2–6 wk. Another reported subcutaneous amount is 200–400 mcg daily in 5–10-day courses. This is a separate shorter pattern from the 2–6-week injectable course above and is not interchangeable with the Deltaran nasal formulation.[12][13]

DSIP is a nine-amino-acid peptide associated with sleep and stress-response signaling. Proposed sleep effects do not establish a dependable insomnia treatment.[1][2][3][12]

DSIP intranasal — deltaran formulation dosage

The documented Deltaran nasal formulation uses 300 mcg once daily for five days. Its concentration and directions define a separate preparation from injectable DSIP.[11]

DSIP is a nine-amino-acid peptide associated with sleep and stress-response signaling. Proposed sleep effects do not establish a dependable insomnia treatment.[5][11][1][2][3]

DSIP transdermal — ex vivo iontophoresis dosage

The iontophoresis experiment loads 3.5 mL of 0.2 mg/mL DSIP solution into the donor chamber, totaling 0.7 mg over 0.785 cm² of excised rabbit-ear skin. Samples are collected over 9 hours while pH, current and enzyme inhibitors are compared. This is a laboratory reservoir amount, not a sleep-treatment patch dose.[6]

The experiment uses cathodal iontophoresis rather than a passive adhesive patch. Its donor concentration, enzyme-inhibitor conditions and measured skin flux describe a laboratory delivery system.[6][1][2][3]

Frequency and timing

The injection pattern is timed 30–60 minutes before bed. The Deltaran nasal formulation and experimental transdermal preparation follow their separate administration schedules.[4][1][2][5][11][12][6]

Cycle length and breaks

Injectable: 2–6 wk. Intranasal — Deltaran formulation: 5 days. Transdermal — ex vivo iontophoresis: 9-hour sampling period. A standard break interval between courses is not established.[12][11][6]

Approval and product quality

DSIP is not an FDA-approved drug.[4][8][9][10]

Side effects and long-term safety

Next-day sedation, dream changes and headache are practical tolerability concerns. Modern dose-ranging, interactions, long-term sleep effects and safety in special populations remain insufficiently characterized.[1][2][3][7]

Route-specific dosing limits

Sedative overlap and underlying sleep or mood disorders are the key safety contexts. Reported-use injectable schedules and additional protocol patterns are not established human treatment regimens or approved product instructions.[1][2][3][7][13][12]